CORAL Study Brings Positive News for Adults With Depression

Video

Coadministration of zuranolone with a standard antidepressant yields positive outcomes.

Sagar Parikh, MD, FRCPC, shares news about the CORAL Study examining zuranolone treatment in patients with major depressive disorder, which demonstrated a rapid and statistically significant reduction in depressive symptoms at day 3 and over the 2-week treatment period.

To read more about this study, see: Improving Depression Symptoms: Study Meets Endpoints.

Dr Parikh is a professor of Depression and Clinical Neuroscience, and Psychiatry Sciences, at the University of Michigan.

Related Videos
Experts on MDD.
Experts on MDD.
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Work takes up one-third of a patient’s life—it is important that we pay attention to it.
Related Content
The results suggest that the bacterium Lactobacillus may aid in the management of stress and in the prevention of these disorders.

Research Explores Connection Between Bacteria and Depression, Anxiety

November 30th 2023
Article
Blue Light Blockers: A Behavior Therapy for Mania

Blue Light Blockers: A Behavior Therapy for Mania

October 7th 2021
Podcast
From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

The Week in Review: November 20-24

November 25th 2023
Article
Treating ‘Morally Objectionable’ Patients

Treating ‘Morally Objectionable’ Patients

September 27th 2021
Podcast
late life TRD

Late-Life Treatment-Resistant Depression

November 20th 2023
Article
From sleep disturbances in ADHD to psychotherapy for treatment-resistant depression, here are highlights from the week in Psychiatric Times.

The Week in Review: November 13-17

November 18th 2023
Article
© 2023 MJH Life Sciences

All rights reserved.